Actinium-225

POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor

Retrieved on: 
Martedì, Settembre 28, 2021
Private Securities Litigation Reform Act, FAP, Program, Tufts University School of Dental Medicine, IND, Actinium-225, SEC, Radiation, Tufts University, Fibroblast, Radionuclide, Molecule, SPLASH, Physician, Adult, Diabetes, MCRPC, Tufts University School of Medicine, Leadership, Technology, Radiopharmaceutical, Survival, Mouse, Neoplasm, Partnership, Therapy, DNA repair, NASDAQ, DNA, Cancer, Company, Terminology, LLC, Risk, Tissue, Forward-looking statement, Enzyme, GLOBE, DPP4, Intention, Patient, Immunotherapy, Prostate cancer, COVID-19, CAFS, Pharmaceutical industry, Medical imaging

INDIANAPOLIS, Sept. 28, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today released additional preclinical data from its fibroblast activation protein-alpha (FAP-alpha) inhibitor program called PNT2004. The new data demonstrates best-in-class characteristics including rapid and persistent tumor targeting with very low retention in normal tissues. Over the duration of the preclinical study, complete tumor regression and prolonged survival were observed. Based on this exciting preclinical data, the Company exercised its option on the technology and amended the exclusive global licensing agreement with Bach Biosciences providing the Company with the opportunity to further expand uses with the highly FAP specific D-Ala-boroPro inhibitor as a targeting warhead.

Key Points: 
  • The new data demonstrates best-in-class characteristics including rapid and persistent tumor targeting with very low retention in normal tissues.
  • D-ala-boroPro is a potent and selective FAP inhibitor that has superior tumor retention and normal tissue clearance.
  • PNT6555 showed >26,000-fold selectivity for FAP over the closely related enzyme DPP4, which is broadly expressed in normal tissues, including kidneys.
  • Information about POINT Biopharma Global Inc.s Phase 3 SPLASH trial for metastatic castrate resistant prostate cancer (mCRPC) patients can be found at https://www.splashtrial.com .

POINT Biopharma Announces Initiation of Randomization for its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC

Retrieved on: 
Giovedì, Settembre 23, 2021
Pharmacokinetics, Achievement, Patient, Radionuclide, Private Securities Litigation Reform Act, NASDAQ, Intention, Cancer, SPLASH, Physician, Prostate cancer, Toxicity, Terminology, ORR, Risk, RPF, COVID-19, Actinium-225, Arbutus Biopharma, Forward-looking statement, Safety, SEC, GLOBE, Pharmaceutical industry, Medical imaging

INDIANAPOLIS, Indiana, Sept. 23, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced that the dosimetry and safety run-in of its Phase 3 SPLASH study evaluating PNT2002 for Metastatic Castrate Resistant Prostate Cancer (mCRPC) met all pre-specified criteria allowing for initiation of the randomization phase without changes to the study design.

Key Points: 
  • I would like to thank our team and partners for enabling the SPLASH trials randomization to begin ahead of schedule, said Dr. Joe McCann, Chief Executive Officer of POINT Biopharma.
  • Our team and partners have done an amazing job of overcoming these difficulties, enabling the achievement of this SPLASH trial milestone.
  • The randomization phase of the study is expected to enroll approximately 400 patients across North America, Europe and the UK.
  • Information about POINT Biopharma Global Inc.s Phase 3 SPLASH trial for metastatic castrate resistant prostate cancer (mCRPC) patients can be found at https://www.splashtrial.com.

BWXT Medical and Bayer AG Enter into Agreement for the Development and Production of Actinium-225

Retrieved on: 
Giovedì, Settembre 16, 2021
Biotechnology, Health, Stem Cells, Pharmaceutical, Oncology, People, Risk, U.S. Securities and Exchange Commission, Automation, Security (finance), Taipei, Radiopharmaceutical, TAT, Form 10-K, Prostate cancer, Nuclear medicine, United States Department of Energy, BWX Technologies, PSMA, Annual report, NYSE, Neoplasm, BWXT, Tat, Radium-223, NASA, Twitter, Radiation, Cancer, Actinium-225, Pharmaceutical industry, Medical imaging

BWXT Medical is a global supplier of medical isotopes and radiopharmaceuticals.

Key Points: 
  • BWXT Medical is a global supplier of medical isotopes and radiopharmaceuticals.
  • Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.
  • BWXT Medical plans to utilize its deep relationships with strategic partners in irradiation services and development of Ac-225.
  • Much like BWXT Medicals other products, processing and manufacturing would then be conducted at BWXT Medical facilities.

NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Retrieved on: 
Mercoledì, Settembre 8, 2021
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices

NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the signing of a supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).

Key Points: 
  • NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the signing of a supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).
  • NorthStar is positioned to be the first commercial-scale producer of Ac-225, applying its radioisotope production technology expertise to provide reliable supply for advancing clinical research and commercial radiopharmaceutical products.
  • A resilient radioisotope supply chain is key to advancing our next-generation pipeline of targeted radiopharmaceuticals, said Dr. Joe McCann, Chief Executive Officer of POINT.
  • NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company that develops, produces and manufactures reliable and environmentally-friendly diagnostic and therapeutic radiopharmaceuticals.

POINT Biopharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Martedì, Settembre 7, 2021

INDIANAPOLIS, Sept. 07, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the Company or POINT), a company accelerating the discovery, development and global access to life changing radiopharmaceuticals, today announced that the Companys Chief Executive Officer, Dr. Joe McCann will present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 13-15, 2021.

Key Points: 
  • INDIANAPOLIS, Sept. 07, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the Company or POINT), a company accelerating the discovery, development and global access to life changing radiopharmaceuticals, today announced that the Companys Chief Executive Officer, Dr. Joe McCann will present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 13-15, 2021.
  • About POINT Biopharma Global Inc.
    POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer.
  • Learn more about POINT Biopharma Global Inc. at https://www.pointbiopharma.com .
  • Information about POINT Biopharma Global Inc.s Phase 3 SPLASH trial for metastatic castrate resistant prostate cancer (mCRPC) patients can be found at https://www.splashtrial.com .

Convergent Therapeutics Appoints Alexander Brown as Chief Operating Officer

Retrieved on: 
Lunedì, Agosto 30, 2021
Actinium, Avelumab, Cancer, Population, Convergent, University, ASCO, Actinium-225, Cornell University, Merck, Prostate, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Man, Therapy, Bachelor of Science, Master of Business Administration, Merck Group, University of Wisconsin–Madison College of Agricultural and Life Sciences, Cabazitaxel, PSMA, Patient, Weill Cornell Medicine, Prostate cancer, Carnegie Mellon University, FDA, ARIAD Pharmaceuticals, Business administration, Merck Serono, Fine chemical, Medical imaging

CAMBRIDGE, Mass., Aug. 30, 2021 /PRNewswire/ --Convergent Therapeutics, a clinical stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers, today announced the appointment of Alexander Brown to the newly created position of Chief Operating Officer.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 30, 2021 /PRNewswire/ --Convergent Therapeutics, a clinical stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers, today announced the appointment of Alexander Brown to the newly created position of Chief Operating Officer.
  • "Alex brings to Convergent extensive commercial and operational expertise, gained from his experience with a number of the industry's top biopharmaceutical companies including Sanofi, Pfizer, Merck KGaA and others," stated Philip Kantoff, M.D., Chief Executive Officer of Convergent Therapeutics.
  • Prior to joining Convergent, Mr. Brown was the Head of New Product Planning, Global Oncology, at Sanofi responsible for the commercial readiness of the company's early-stage oncology pipeline.
  • Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers.

POINT Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Venerdì, Agosto 13, 2021
Somatostatin, ORR, Administration, NETS, Forward-looking statement, NASDAQ, PNT, RPF, PIPE, Terminology, Therapeutic index, MCRPC, Radionuclide, Research, Advertising, Company, Actinium-225, SPLASH, Private Securities Litigation Reform Act, Accounting, Patient, COVID-19, Program, Technology, IND, GLOBE, Regulatory affairs, Intention, Pharmacokinetics, SEC, Risk, Family, RAC, Toxicity, PSMA, Neoplasm, Development, Cash, TME, NRC, State Administrative Expenses, Cancer, Safety, Prostate cancer, Medical imaging, Pharmaceutical industry

INDIANAPOLIS, Aug. 13, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life changing radiopharmaceuticals, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.

Key Points: 
  • INDIANAPOLIS, Aug. 13, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the Company or POINT), a company accelerating the discovery, development and global access to life changing radiopharmaceuticals, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.
  • During Q2 2021, POINT listed on NASDAQ and now has $273.7 million of cash to transform POINT into a global radioligand leader, said Dr. Joe McCann, Chief Executive Officer of POINT.
  • Cash and Cash Equivalents: As of June 30, 2021, POINT had approximately $273.7 million in cash and cash equivalents.
  • About POINT Biopharma Global Inc.
    POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer.

POINT Biopharma Announces Early Completion of enrollment and initial dosing in the Lead-In of its Phase 3 SPLASH study of PNT2002 for mCRPC

Retrieved on: 
Martedì, Agosto 10, 2021
Intention, ORR, Achievement, Safety, Company, Patient, Physician, Private Securities Litigation Reform Act, Risk, United Kingdom, Radionuclide, MCRPC, Cancer, RPF, Forward-looking statement, European Union, Prostate, SPLASH, Actinium-225, COVID-19, Â, Terminology, Prostate cancer, Pharmacokinetics, SEC, NASDAQ, GLOBE, Pharmaceutical industry, Medical imaging

Patient enrollment and initial dosing was completed significantly ahead of schedule, said Dr. Joe McCann, Chief Executive Officer of POINT Biopharma.

Key Points: 
  • Patient enrollment and initial dosing was completed significantly ahead of schedule, said Dr. Joe McCann, Chief Executive Officer of POINT Biopharma.
  • Patient treatment and follow-up remain ongoing, and the Company expects to report data from this phase of the study at a future scientific conference.
  • The next phase of the study is expected to enroll approximately 400 patients across North America, Europe and the UK.
  • Information about POINT Biopharma Global Inc.s Phase 3 SPLASH trial for metastatic castrate resistant prostate cancer (mCRPC) patients can be found at https://www.splashtrial.com.

First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer

Retrieved on: 
Mercoledì, Agosto 4, 2021
GenesisCare, Man, Research, Degenerative disease, Solution, Australian Securities Exchange, Tat, Principal, Technology, Physician, MTR, Surgical oncology, Pharmacokinetics, Program, Patient, Glutamate carboxypeptidase II, Nuclear medicine, Cancer, Actinium-225, Oncology, PET, Antibody, Radiation, TLX, Precision medicine, Prostate, Prostate cancer, Drug development, Liver, Safety, Cardiology, TGA, LinkedIn, GLOBE, Pharmaceutical industry, Medical imaging, Medicine

MELBOURNE, Australia, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces today that the first patient has been dosed in its CUPID first-in-human Phase I study of the Companys next generation prostate cancer therapy candidate TLX592 in patients with advanced prostate cancer.

Key Points: 
  • MELBOURNE, Australia, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces today that the first patient has been dosed in its CUPID first-in-human Phase I study of the Companys next generation prostate cancer therapy candidate TLX592 in patients with advanced prostate cancer.
  • This investigational agent will become Telixs first targeted alpha therapy (TAT) for the treatment of patients with advanced prostate cancer.
  • TLX592 targets prostate specific membrane antigen (PSMA)1, as does the Companys existing TLX591 (177Lu-rosapatamab) prostate cancer therapy program.
  • The very high energy, short range properties of targeted alpha therapy have the potential to offer a potent and highly selective anti-cancer therapy to patients with advanced prostate cancer.

Evergreen Theragnostics Expands Alpha Radiopharmaceutical Production Capabilities

Retrieved on: 
Giovedì, Luglio 15, 2021
Contract manufacturing organization, Pharmaceutical industry, Evergreen, Software

SPRINGFIELD, N.J., July 15, 2021 /PRNewswire/ -- Evergreen Theragnostics, Inc., a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), has undertaken an important strategic expansion at its manufacturing facility in Springfield, NJ

Key Points: 
  • SPRINGFIELD, N.J., July 15, 2021 /PRNewswire/ -- Evergreen Theragnostics, Inc., a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), has undertaken an important strategic expansion at its manufacturing facility in Springfield, NJ
    With the Evergreen Springfield Facility set to open within the next two months, Evergreen has already begun expansion to build a GMP state-of-the-art alpha emitter production center, which will be integrated into Evergreen's existing facility.
  • The addition, opening in Q1 2022, will bolster Evergreen's ability to support alpha based radiopharmaceutical programs from pre-clinical pharmaceutical development to commercial manufacture and supply.
  • We firmly believe that this approach will greatly accelerate the delivery of novel treatments to patients," said James Cook, Evergreen Theragnostics CEO.
  • Evergreen Theragnostics, established in 2019, is a leading US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO).